Association of cannabis, cannabidiol and synthetic cannabinoid use with mental health in UK adolescents DOI Creative Commons
James Hotham, Rebecca Cannings‐John, Laurence Moore

et al.

The British Journal of Psychiatry, Journal Year: 2023, Volume and Issue: 223(4), P. 478 - 484

Published: July 24, 2023

Background Cannabis has been associated with poorer mental health, but little is known of the effect synthetic cannabinoids or cannabidiol (often referred to as CBD). Aims To investigate associations cannabis, and health in adolescence. Method We conducted a cross-sectional analysis 13- 14-year-old adolescents across England Wales 2019–2020. Multilevel logistic regression was used examine association lifetime use self-reported symptoms probable depression, anxiety, conduct disorder auditory hallucinations. Results Of 6672 who participated, 5.2% reported using 1.9% 0.6% cannabinoids. After correction for multiple testing, had these substances were significantly more likely report depressive, anxiety disorder, well hallucinations, than those not. Adjustment socioeconomic disadvantage on associations, weekly tobacco resulted marked attenuation associations. The cannabis depressive disorders weaker did There evidence an interaction between cannabidiol. Conclusions our knowledge, this study provides first general population that are These require replication, ideally prospective cohorts stronger designs.

Language: Английский

Adult use of highly-potent Δ9-THC cannabis concentrate products by U.S. state cannabis legalization status, 2021 DOI
Deborah S. Hasin, Jacob T. Borodovsky, Dvora Shmulewitz

et al.

Addictive Behaviors, Journal Year: 2023, Volume and Issue: 140, P. 107617 - 107617

Published: Jan. 9, 2023

Language: Английский

Citations

20
Cannabis-Related Disorders and Toxic Effects DOI
David A. Gorelick

New England Journal of Medicine, Journal Year: 2023, Volume and Issue: 389(24), P. 2267 - 2275

Published: Dec. 13, 2023

Language: Английский

Citations

18
How should policymakers regulate the tetrahydrocannabinol content of cannabis products in a legal market? DOI Creative Commons
Wayne Hall, Janni Leung, Beatriz H. Carlini

et al.

Addiction, Journal Year: 2023, Volume and Issue: 118(6), P. 998 - 1003

Published: Jan. 20, 2023

An increased use of high-potency cannabis products since legalization in the United States, Canada and elsewhere may increase cannabis-related harm. Policymakers have good reasons for regulating more potent ways that minimize harm, using approaches similar to those used regulate alcohol; namely, banning sale cannabis, setting a cap on tetrahydrocannabinol (THC) content imposing higher rates taxes products. Given difficulty US policymakers had extracts edibles, governments are planning legalize need put policies into enabling legislation evaluate impact these harms.

Language: Английский

Citations

17
Increasing risk of cannabis use disorder among U.S. veterans with chronic pain: 2005-2019 DOI
Zachary L. Mannes, Carol A. Malte, Mark Olfson

et al.

Pain, Journal Year: 2023, Volume and Issue: 164(9), P. 2093 - 2103

Published: May 8, 2023

Abstract In the United States, cannabis is increasingly used to manage chronic pain. Veterans Health Administration (VHA) patients are disproportionately affected by pain and may use for symptom management. Because increases risk of disorders (CUDs), we examined time trends in CUD among VHA with without pain, whether these differed age. From electronic health records from 2005 2019 (∼4.3-5.6 million yearly), extracted diagnoses conditions ( International Classification Diseases [ ICD ]- 9-CM , 2005-2014; ICD-10-CM 2016-2019). Differential prevalence overall age-stratified (<35, 35-64, or ≥65) were assessed any number (0, 1, ≥2). 2014, increased significantly more (1.11%-2.56%) than those (0.70%-1.26%). Cannabis disorder across all age groups was highest ≥2 conditions. 2016 2019, ≥65 (0.63%-1.01%) (0.28%-0.47%) Over time, has other patients, increase ≥65. Clinicians should monitor symptoms others who cannabis, consider noncannabis therapies, particularly because effectiveness management remains inconclusive.

Language: Английский

Citations

17
Development of an anxiety disorder following an emergency department visit due to cannabis use: a population-based cohort study DOI Creative Commons
Daniel T. Myran,

Lyndsay D. Harrison,

Michael Pugliese

et al.

EClinicalMedicine, Journal Year: 2024, Volume and Issue: 69, P. 102455 - 102455

Published: Feb. 5, 2024

BackgroundThere is ongoing uncertainty about whether cannabis use increases the risk of developing an anxiety disorder. In this study we estimated having incident healthcare visit for disorder following emergency department (ED) and explored factors associated with increased risk.MethodsWe used health administrative data to perform a population-based cohort all individuals aged 10–105 years no previous visits disorders in Ontario, Canada, between January 2008 March 2019. We compared ED or hospital (primary analysis) additionally outpatient setting (secondary members general population using cumulative incidence functions cause-specific hazard models adjusted relevant confounders.FindingsOur included 12,099,144 without prior care hospital, which 34,822 (0.29%) had due cannabis. Within 3-years cannabis, 12.3% (n = 4294) hospitalization disorder—a 3.7-fold (adjusted Hazard Ratio [aHR] 3.69 95% CI 3.57–3.82) relative (1.2%). secondary analysis, further excluding disorders, 23.6% visit, within 5.6% (aHR 3.88 3.77–2.99). The was higher across age sex strata. However, younger males 5.67 5.19–6.21) greater than women 3.22 2.95–3.52).InterpretationED were disorder, particularly young males. These findings have important clinical policy implications given increasing over time trend towards legalization cannabis.FundingCanadian Institutes Health Research.

Language: Английский

Citations

8
CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions DOI Creative Commons
Lixuan Qian, Jessica L. Beers, Klarissa D. Jackson

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(4), P. 484 - 484

Published: April 1, 2024

Cannabinoid use has surged in the past decade, with a growing interest expanding cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) applications into special populations. Consequently, increased of CBD THC raises risk drug–drug interactions (DDIs). Nevertheless, DDIs for cannabinoids, especially populations, remain inadequately investigated. While some clinical trials have explored between therapeutic drugs like antiepileptic CBD/THC, more potential to be examined. This review summarizes published studies on THC–drug interactions, outlines mechanisms involved, discusses physiological considerations pharmacokinetics (PK) DDI populations (including pregnant lactating women, pediatrics, older adults, patients hepatic or renal impairments, others), presents modeling approaches that can describe associated The PK poorly characterized, limited investigating involving CBD/THC these Therefore, it is critical evaluate medications are commonly used Modeling aid understanding interactions.

Language: Английский

Citations

7
Germany's cannabis act: a catalyst for European drug policy reform? DOI Creative Commons
Jakob Manthey,

Jürgen Rehm,

Uwe Verthein

et al.

The Lancet Regional Health - Europe, Journal Year: 2024, Volume and Issue: 42, P. 100929 - 100929

Published: May 14, 2024

With the enforcement of Cannabis Act on 1 April 2024, Germany has adopted one most liberal legal approaches to cannabis continent. The German model prioritises a non-profit approach and precludes market mechanisms. We believe these are main drivers for increasing use related health problems, based observations following legalisation in Canada many states U.S. Although legalising possession cultivation may not immediately eliminate illegal market, it is expected serve public goals. Despite overall positive evaluation Germany, there three potential areas concern: misuse medical system, normalization use, influence industry. herald beginning new generation European policies, but concerted efforts will be required ensure that policy reforms rather than undermine

Language: Английский

Citations

7
Recommendations for Reducing the Risk of Cannabis Use-Related Adverse Psychosis Outcomes: A Public Mental Health-Oriented Evidence Review DOI Creative Commons
Benedikt Fischer, Wayne Hall, Thiago Marques Fidalgo

et al.

Journal of Dual Diagnosis, Journal Year: 2023, Volume and Issue: 19(2-3), P. 71 - 96

Published: July 3, 2023

Objective: Cannabis use is increasingly normalized; psychosis a major adverse health outcome. We reviewed evidence on cannabis use-related risk factors for outcomes at different stages toward recommendations reduction by individuals involved in use. Methods: searched primary databases pertinent literature/data 2016 onward, principally relying reviews and high-quality studies which were narratively summarized quality-graded; developed international expert consensus. Results: Genetic risks, mental health/substance problem histories elevate the risks cannabis-related psychosis. Early age-of-use-onset, frequency-of-use, product composition (i.e., THC potency), mode other substance co-use all influence risks; protective effects of CBD are uncertain. Continuous may adversely affect psychosis-related treatment medication effects. Risk factor combinations further amplify odds outcomes. Conclusions: Reductions identified factors—short abstinence—may decrease related outcomes, thereby protect users' health.

Language: Английский

Citations

15
High potency cannabis use, mental health symptoms and cannabis dependence: Triangulating the evidence DOI Creative Commons
Kat Petrilli, Lindsey A. Hines, Sally Adams

et al.

Addictive Behaviors, Journal Year: 2023, Volume and Issue: 144, P. 107740 - 107740

Published: April 24, 2023

Cannabis potency (concentration of Δ-9-Tetrahydrocannabinol) has been associated with risks adverse mental health outcomes and addiction but no studies have triangulated evidence from self-report objective measures cannabis potency. We hypothesised that users high would higher levels (a) anxiety, (b) depression (c) psychosis-like symptoms (d) dependence than lower cannabis.A cross-sectional study 410 participants donated a sample for analysis THC concentration reported their preference. These two exposure were investigated association dependence, depression, in separate linear/logistic regression models.High preference was slight increased risk after adjusting confounding, the exception use frequency (OR = 1.16, 95% CI 1.04-1.28). No found between dependence. There weak small anxiety. or symptoms.Users who preferred types might be at problematic use. This should considered caution as we not able to triangulate these results an measure More research is needed understand

Language: Английский

Citations

14
A systematic review of evidence on integrated management of psychiatric disorders in youth who use cannabis DOI Creative Commons
Carol Vidal, Kevin M. Simon, Caroline Brooks

et al.

Drug and Alcohol Dependence Reports, Journal Year: 2024, Volume and Issue: 10, P. 100216 - 100216

Published: Jan. 4, 2024

Given the risks to mental health associated with cannabis use in youth and increase legalization worldwide U.S., there is a need understand existing evidence-based approaches integrated management of psychiatric disorders who cannabis. This systematic review aimed appraise current evidence on treatment for adolescents young adults common engage regular use. A total 989 studies were screened inclusion. Study's titles abstracts advanced full text further screening by two independent reviewers. Thirty-five full-text articles reviewed, five ultimately meeting all criteria Five randomized controlled trials examined effects therapeutic interventions used cannabis, including depression, one bipolar disorder, anxiety PTSD reviewed. No considered high risk bias. Overall, paucity research comorbid adolescent use, which limits ability draw recommendations.

Language: Английский

Citations

5